



Reduction of common stock

With reference to company announcement no. 3/2019, a reduction of the company's B common stock by DKK 12,000,000 via cancellation of 6,000,000 treasury B stocks, was adopted at Novozymes A/S' Annual Shareholders' Meeting on February 27, 2019.

Today, Novozymes has registered the final implementation of the reduction of its common stock with the Danish Business Authority. Consequently, the reduction of Novozymes' B common stock from DKK 486,512,800 to DKK 474,512,800 has been completed.

After the reduction, the common stock is DKK 582,000,000, distributed on 291 million stocks of DKK 2 per stock.

Common stock overview	Common stock, DKK	Number of stocks, DKK 2
A common stock	107,487,200	53,743,600
B common stock	474,512,800	237,256,400
Total	582,000,000	291,000,000

On March 29, 2019, following the reduction of its common stock, Novozymes' holding of treasury shares were 3.4 million B shares, equivalent to 1.2% of the reduced total share capital.

March 29, 2019
Company announcement No. 4

Contact information
novozymesIR@novozymes.com

Tobias Cornelius Björklund
+45 3077 8682
tobb@novozymes.com

Carl Ahlgren
+45 3077 2783
cxal@novozymes.com

About Novozymes

Novozyymes is the world leader in biological solutions. Together with customers, partners and the global community, we improve industrial performance while preserving the planet's resources and helping build better lives. As the world's largest provider of enzyme and microbial technologies, our bioinnovation enables higher agricultural yields, low-temperature washing, energy-efficient production, renewable fuel and many other benefits that we rely on today and in the future. We call it Rethink Tomorrow. www.novozymes.com

Novozyymes A/S CVR number: 10 00 71 27 LEI: 529900T6WNZXD2R3JW38

Novozyymes A/S
Krogshøjvej 36
2880 Bagsvaerd
Denmark

Phone: +45 4446 0000

Rethink Tomorrow

novozymes 